We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01167101
First Posted: July 22, 2010
Last Update Posted: September 4, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Shin, Woon Geon, Kangdong Sacred Heart Hospital
  Purpose
Treatment strategy of post endoscopic submucosal dissection (ESD) ulcer is not yet conclusive. Rebamipide is a mucosal protective agent widely used in East Asia and has good effect on quality of ulcer healing (QOUH). The investigators will conduct this randomized controlled study to assess the effect of a combination therapy of rebamipide and proton pump inhibitor (PPI) on post ESD ulcer healing.

Condition Intervention
Stomach Ulcer Drug: Rebamipide Drug: pantoprazole

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? : Multicenter, Randomized, and Prospective Study

Resource links provided by NLM:


Further study details as provided by Shin, Woon Geon, Kangdong Sacred Heart Hospital:

Primary Outcome Measures:
  • Healing efficacy of Rebamipide in the treatment of iatrogenic gastric ulcer [ Time Frame: at 2month after endoscopic submucosal dissection (ESD) ]
    Healing efficacy will be assessed by the change of ulcer size. Quality of Ulcer Healing(QOUH) wil be assessed by nodularity in the healed ulcer by two endoscopist.


Enrollment: 290
Study Start Date: May 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Pantoprazole
controls Pantoprazole 40mg qd for 28days
Drug: pantoprazole
pantoprazole 40mg qd for 28days
Active Comparator: Pantoprazole + Rebamipde
Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days
Drug: Rebamipide
Rebamipide 100mg Tid for 28days
Drug: pantoprazole
pantoprazole 40mg qd for 28days

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients underwent ESD for gastric adenoma or cancer

Exclusion Criteria:

  • subjects with previous gastric surgery
  • subjects taking aspirin, anticoagulant, or antiplatelet agent
  • subjects having malignancy except gastric cancer
  • pregnant or breast-feeding women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01167101


Locations
Korea, Republic of
Kangdong Sacred Heart Hospital
Seoul, Korea, Republic of, 134-701
Sponsors and Collaborators
Kangdong Sacred Heart Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Shin, Woon Geon, Professor, Kangdong Sacred Heart Hospital
ClinicalTrials.gov Identifier: NCT01167101     History of Changes
Other Study ID Numbers: 08-62
First Submitted: July 20, 2010
First Posted: July 22, 2010
Last Update Posted: September 4, 2015
Last Verified: September 2015

Keywords provided by Shin, Woon Geon, Kangdong Sacred Heart Hospital:
Rebamipide
gastric ulcer
healing rate
iatrogenic gastric ulcer after endoscopic submucosal dissection

Additional relevant MeSH terms:
Ulcer
Stomach Ulcer
Pathologic Processes
Peptic Ulcer
Duodenal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Pantoprazole
Rebamipide
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antioxidants
Protective Agents
Physiological Effects of Drugs